Abstract
Congenital cytomegalovirus (CMV) infection is a major cause of disability in newborns. In spite of knowledge that maternal immunity to CMV protects newborns against these disabilities, there is no licensed vaccine for CMV. The barriers to availability of a CMV vaccine include: (1) a lack of knowledge about the problem; (2) an incomplete understanding of the immune correlates of protection; and (3) uncertainty about what the proper target population is for vaccination. This review summarizes the current state of CMV vaccines and discusses the obstacles that must be overcome before the goal of a vaccine can be realized.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 243-250 |
| Number of pages | 8 |
| Journal | Drug Discovery Today: Therapeutic Strategies |
| Volume | 3 |
| Issue number | 2 |
| DOIs | |
| State | Published - 2006 |
Bibliographical note
Funding Information:Supported by NIH HD038416 and HD044864, and a grant from the March of Dimes Birth Defects Foundation.
